<DOC>
	<DOCNO>NCT01477775</DOCNO>
	<brief_summary>A subset patient recruit main MATRIX study randomize intervention discharge standard care ( treat physician decide oral P2Y12 inhibitor add top aspirin ) versus customize approach base algorithm integrates phenotypic information , include limited residual on-treatment platelet reactivity assess via VerifyNow P2Y12 Assay .</brief_summary>
	<brief_title>Customized Choice Oral P2Y12 Receptor Blocker</brief_title>
	<detailed_description>Up 20-30 % clopidogrel treat patient adequately respond drug high risk ischemic event include death , myocardial infarction , stroke stent thrombosis . Residual high on-treatment platelet reactivity patient clopidogrel depend complex interplay phenotypic ( spontaneous platelet reactivity , inflammatory status , acuity clinical presentation , age , renal function ) genetic variable . Two main Loss function allele identify : 1 ) CYP450 2C19*2 present around 25 % Caucasian population result lower amount clopidogrel active metabolite . Carriers 2C19*2 high risk death MI 2.7 fold increase risk stent thrombosis treat conventional clopidogrel ; 2 ) ABCB-1 C carrier reduce clopidogrel absorption similarly show high risk ischemic adverse event treat clopidogrel . Many investigator recently show however , positive predictive value genetic test alone time PCI limit knowledge genetic status alone respect two previously describe loss function alleles poorly able identify long-term clopidogrel poor responder . An Algorithm therefore develop , combine phenotype information show risk stratify ischemic bleeding event one year follow-up PCI patient . This algorithm develop single center retrospective registry . To prospectively validate context prospective multicenter study , first 320 patient recruit present study undergo phenotype discharge 30 day genotype assessment time randomization , irrespective group assign ( i.e . standard care gene phenotype ) . The hypothesis behind mechanistic sub-study use combine phenotype-genotype algorithm increase proportion patient 30 day therapeutic range accord PRU value 50 % standard care versus 70 % gene phenotype group .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>patient recruit main MATRIX study underwent coronary angioplasty stent placement . unwillingness sign sub study specific inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>myocardial infarction</keyword>
	<keyword>coronary stent</keyword>
	<keyword>Oral P2Y12 receptor blocker</keyword>
	<keyword>Platelet reactivity unit ( PRU )</keyword>
</DOC>